Bruce Power has received approval from the Canadian Nuclear Safety Commission (CNSC) to take the next step forward for new isotope production becoming the first power reactor globally to commercially produce Lutetium-177, an innovative therapeutic isotope used in the treatment of prostate cancer and neuroendocrine tumors.
“This Project is an innovative partnership between Bruce Power, IsoGen, Saugeen Ojibway Nation (SON) and ITM and is a game changer for the supply of medical isotopes and the global medical community in the fight against cancer,” said James Scongack, Bruce Power Chief Development Officer and EVP Operational Services. “This is another important step forward to utilize our CANDU reactors to provide a new large-scale capacity for production in the medical isotope supply chain, cementing Canada’s place as a global isotope superpower.”
Isogen is a joint venture between Framatome and Kinectrics to enable the use of CANDU reactors to produce medical isotopes needed to treat and diagnose patients with serious diseases world-wide.
“The Framatome team conducted extensive research and development in Canada and modified German technology for use in a CANDU reactor, which resulted in the first Isotope Production System in a power reactor for commercial production of therapeutic medical isotopes,” said Curtis Van Cleve, President and CEO of Framatome Canada Ltd. “We applaud our partners at Bruce Power for their commitment to innovation that supports the continuous production of both electricity and medical isotopes, and to harnessing the therapeutic power of nuclear energy.”
The Isotope Production System (IPS), designed and manufactured by Isogen, will be used to produce Lutetium-177, an isotope used in nuclear medicines that allows for targeted and precise treatments, destroying cancer cells while limiting damage to surrounding healthy tissue and organs. The irradiated Ytterbium targets obtained from the IPS will be processed at ITM premises, where the highly pure no-carrier-added (n.c.a.) Lutetium-177 will be produced in pharmaceutical quality. N.c.a. Lutetium-177 will be marketed globally by ITM under the brand name EndolucinBeta® as well as leveraged for clinical supply to advance the company’s own pipeline. ITM is a German based leading radiopharmaceutical biotech company focused on the development, production and global supply of medical radioisotopes and radiopharmaceuticals.
“The license granted by CNSC today marks a critical milestone for Isogen on our mission to provide lifesaving medical isotopes to the world,” said David Harris, CEO of Kinectrics. “This approval showcases the advantages of bringing together the significant investments and capabilities of the partners to advance the technology, and develop the safety, engineering and licensing packages necessary to introduce such a cutting-edge technology in a safe and reliable manner without impact to normal reactor operation.”